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Abstract
Background: The mucosal pathogenesis of HIV has been shown to be an important feature of infection and
disease progression. HIV-1 infection causes depletion of intestinal lamina propria CD4+ T cells (LPL), therefore,
intestinal CD4+ T cell preservation may be a useful correlate of protection in evaluating vaccine candidates.
Vaccine studies employing the cat/FIV and macaque/SIV models frequently use high doses of parenterally
administered challenge virus to ensure high plasma viremia in control animals. However, it is unclear if loss of
mucosal T cells would occur regardless of initial viral inoculum dose. The objective of this study was to determine
the acute effect of viral dose on mucosal leukocytes and associated innate and adaptive immune responses.
Results: Cats were vaginally inoculated with a high, middle or low dose of cell-associated and cell-free FIV. PBMC,
serum and plasma were assessed every two weeks with tissues assessed eight weeks following infection. We found
that irrespective of mucosally administered viral dose, FIV infection was induced in all cats. However, viremia was
present in only half of the cats, and viral dose was unrelated to the development of viremia. Importantly,
regardless of viral dose, all cats experienced significant losses of intestinal CD4+ LPL and CD8+ intraepithelial
lymphocytes (IEL). Innate immune responses by CD56+CD3- NK cells correlated with aviremia and apparent occult
infection but did not protect mucosal T cells. CD4+ and CD8+ T cells in viremic cats were more likely to produce
cytokines in response to Gag stimulation, whereas aviremic cats T cells tended to produce cytokines in response to
Env stimulation. However, while cell-mediated immune responses in aviremic cats may have helped reduce viral
replication, they could not be correlated to the levels of viremia. Robust production of anti-FIV antibodies was
positively correlated with the magnitude of viremia.
Conclusions: Our results indicate that mucosal immune pathogenesis could be used as a rapid indicator of
vaccine success or failure when combined with a physiologically relevant low dose mucosal challenge. We also
show that innate immune responses may play an important role in controlling viral replication following acute
mucosal infection, which has not been previously identified.
Background
The recent failure of the STEP clinical trial of the
MRKAd5 HIV-1 gag/pol/nef vaccine has raised impor-
tant questions about vaccine development for HIV-1
[1-3]. Participants in the Phase I trial had robust mea-
surable T cell responses to vaccination [4]; similar
robust T-cell responses were observed in participants in
the Phase IIB trial, however, they afforded no protection
against HIV-1 infection as compared to the control
group [5]. These data suggest that measurable in vitro T
cell responses of the participants were not a reliable pre-
dictor of vaccine protection. Identification of appropriate
and reliable correlates of protection has been elusive in
pathogenesis and vaccine studies. Many potential immu-
nologic correlates have been suggested including cyto-
toxic CD8+ T cells, neutralizing antibodies, and
preservation of memory and effector lymphocyte popu-
lations in the gastrointestinal mucosa [6]. However,
numerous studies examining the role of T cell and anti-
body responses in the protection of highly-exposed
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of viral replication in elite controllers (EC) and long-
term non-progressors (LTNP) [7-12], have yielded con-
flicting results [13-16].
Collectively, these observations raise new questions
about defining correlates of protection and how they
could be more clearly distinguished in the context of
future vaccine trials [17,18]. Further, as animal model
vaccine trials appeared to show the MRKAd5 vaccine to
be protective [19-23], the design and assumptions used
in animal model vaccine trials might also need to be
reconsidered.
Vaccine studies using animal models often employ
high doses of challenge virus to ensure a high viral set
point in control animals so that a reduction of viral bur-
den in vaccinated animals can be used as an indicator of
efficacy. Unfortunately, high challenge doses do not
mimic natural infection and could lead to flawed con-
clusions about the true efficacy of a vaccine [24]. The
majority of HIV-1 infections occur via the mucosal
route [25]. Certain studies suggest that infection can
occur in serodiscordant couples with repeated sexual
exposure from their HIV-1 positive partners who have
plasma viral loads ranging from 5-400 copies/ml [26].
These observations suggest that high viral challenge
doses are not physiologically relevant in natural HIV
transmission. Further, animal model studies have shown
that low dose infection can result in either productive
or latent infection [27-31]. In contrast, several investiga-
tors have suggested that low viral dose may be partially
responsible for individuals who are either HEPS or
LTNP [32-34]. Importantly, the effect of initial viral
dose on the presence and severity of mucosal pathogen-
esis is unclear, in particular when the route of infection
is via the reproductive mucosa. Therefore, a better
understanding of the relationship between viral dose,
mucosal pathogenesis and mucosal immune response
would enhance our ability to design and interpret vac-
cine trials.
In the present study, we employed the well-described
cat/feline immunodeficiency virus (FIV) model [35-39]
to investigate the relationship between viral dose and
immune pathogenesis. We vaginally challenged three
groups of cats with different infectious doses of cell-
associated and cell-free FIV to determine the effect of
viral dose on mucosal leukocyte populations. To address
possible correlates of protection, we assessed the role of
innate, cell-mediated, and humoral immune responses
in acute FIV infection to determine if any of these
immune responses were associated with decreased viral
dissemination and protection of the gastrointestinal
mucosa. These studies provide new insight into early
mechanisms of control over viral replication, with parti-
cular emphasis on the responses in the mucosa.
Results
Viral load
Cats vaginally infected with high, middle, or low doses
of cell-associated and cell-free virus were evaluated for
v i r a ll o a db yP C Ra n dv i r u si s o l a t i o n .F i g u r e1s u m -
marizes mean plasma viral load for each group. Peak
viremia was detected at four weeks post-infection in all
groups, with plasma viremia detected in 4/6 high (range,
2.2 × 10
4 to 2.0 × 10
3 copies/ml plasma), 3/6 middle
(range, 1.8 × 10
4 to 1.5 × 10
2 copies/ml plasma) and 2/5
low (range, 2.4 × 10
4 to 1.7 × 10
2 copies/ml plasma)
dose inoculated cats. Provirus in PBMC was detected in
3/6 high, 1/6 middle and 2/5 low dose inoculated cats.
Virus was isolated from unfractionated bone marrow in
5/6 high, 5/6 middle, and 5/5 low dose inoculated cats.
By at least one of these measures, each cat, regardless of
inoculum dose, was infected with FIV. Interestingly,
although shown to be infected, eight cats did not have
detectible plasma viremia.
Effect of FIV infection on CD4+ and CD8+ T cell numbers
Two weeks post-infection, absolute CD4+ T cell num-
bers in PBMC (Figure 2A) were decreased in the high (p
= 0.002) and middle (p = 0.06) dose groups, whereas the
low dose group experienced a modest decrease by four
weeks post-infection that was not significant. All three
groups had comparable mean CD4+ T cell numbers at
study end; mean levels which were lower than pre-infec-
tion levels. Importantly, the presence or absence of vire-
mia was not correlated with absolute CD4+ T cell
numbers (Figure 2B). All dose groups had similar reduc-
tions in CD4:CD8 ratio over the course of the study
(Figure 2C).
No significant changes in CD4+ T cell percentages
were observed in PBMC, lymph nodes, spleen or thymus
for any group (Figure 3), however, a significant decrease
in LPL CD4+ T cell percentages, averaging a 57% loss
as compared to control cats, was noted regardless of
Figure 1 Mean plasma viral RNA. Plasma from blood sampled at
weeks 0, 2, 4, 6 and 8 post-infection was evaluated for viral RNA
using real-time PCR. Mean viral RNA copies per ml of plasma are
shown for high, middle and low dose groups.
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Page 2 of 14inoculum dose (Figure 4A). The loss of CD4+ LPL was
further magnified considering a significant loss in total
yield of LPL occurred (mean control LPL yield was 6.80
×1 0
7 vs. FIV-infected LPL yield of 3.94 × 10
7,p=
0.00037). Furthermore, a significant decrease in the per-
centage of CD8a+a n dC D 8 b+ T cells was found in IEL
from all dose groups as compared to controls (Figure
4B,C). As CD8aa+a n dC D 8 ab+ T cells serve different
functions in the epithelial compartment, we also
assessed if either of these populations was specifically
lost. CD8ab+ T cells were significantly decreased in all
dose groups, compared to controls (ANOVA, p <
0.001). CD8aa+ T cell percentages were not signifi-
cantly decreased in FIV-infected cats (p = 0.1311), how-
ever, the overall trend showed decreased percentages in
FIV-infected cats [18.11%] versus controls [24.85%].
Innate immune response
While all study cats were infected with FIV, a few cats
in each dose group did not become viremic. To identify
immunologic populations that might mediate the appar-
ent control of viremia, we assessed total NK cells (CD56
+CD3+/-), classic NK cells (CD56+CD3-) and NKT cells
(CD56+CD3+) in blood, draining lymph node (data not
shown), spleen, and IEL. Total CD56+ NK cell expres-
sion was significantly decreased in FIV-infected cats as
compared to control cats in each site at eight weeks
post infection (Figure. 5A). Figure 5(B) and 5(C) show
NKT cell and classic NK cell percentages, respectively,
in viremic, non-viremic and control cats. NKT cell per-
centages were significantly reduced in PBMC and spleen
from FIV-infected cats, regardless of viremia status. In
contrast, CD56+CD3- NK cells were significantly
decreased only in viremic cats.
Cell-mediated immune responses
Anti-Gag and anti-Env specific CD4+ and CD8+ T cell
responses were assessed in PBMC, peripheral and drain-
ing lymph nodes, spleen, IEL and LPL (Figure. 6 and
data not shown). Cells were stimulated for six hours
with peptide pools for Gag and Env [40], and then intra-
cellular IL-2, IFNg,a n dT N F a production was deter-
mined in CD4+ and CD8+ T cells. No differences in
cytokine production were found when comparing
g r o u p sb a s e do ni n o c u l u md o s e( d a t an o ts h o w n ) .D i f -
ferences in IFNg and IL-2 production were compared
on the basis of presence or absence of viremia.
Responses in viremic cats tended to be directed to
Gag rather than Env peptides, whereas non-viremic cats
had a similar magnitude of response to both Gag (data
not shown) and Env peptides. Significant differences
were noted in viremic cats when comparing the produc-
tion of IFNg by CD4+ and CD8+ T cells from the
lamina propria in response to Gag versus Env peptides.
Figure 2 Absolute CD4+ T cell count in PBMC. Blood sampled at
weeks 0, 2, 4, 6 and 8 post-infection was evaluated for phenotypic
expression of CD4+ T cells and calculated based on total WBC
counts with differential cell count assessed from cytological
evaluation. Mean and standard deviation for absolute CD4+ T cell
counts are presented for high, middle and low dose groups (A), and
based on presence or absence of viremia (B). Mean and standard
errors for the CD4:CD8 ratio are shown for all dose groups
combined (C). Statistics were calculated using ANOVA comparing
baseline week with post-infection samples within each group.
Significance shown using p-values, with * p < 0.01 and # p = 0.06.
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w h i c hp r o d u c e db o t hI L - 2a n dI F N g against Gag pep-
tides, but not Env peptides.
FIV-infected, non-viremic cats were more likely to
produce cytokines in response to Env peptide stimula-
tion as compared to viremic cats. This was evident in
CD4+ and CD8+ IFNg specific responses in LPL, IL-2
responses in the draining lymph node (ILN), and IL-2
+IFNg+ producing cells in the ILN. Compared to vire-
m i ap o s i t i v ec a t s ,n o n - v i r e m i cc a t sa l s os h o w e ds i g n i f i -
cant differences in anti-Env responses in CD4+ IL-2
producing PBMC. CD8+ IL-2 producing PBMC also
showed a marked difference (p = 0.06). The trend of
anti-Env responses was also identified in CD4+IL-2
+IFNg+ LPL and CD8+IL-2+IFNg+ splenocytes.
Humoral immune responses
To understand the contribution humoral immunity may
have played in control of viremia, we assessed anti-Gag
and anti-Env responses in serum and vaginal wash sam-
ples using a highly sensitive chemiluminescent ELISA
assay. Two cats did not produce antibodies against
either Gag or Env, three cats produced antibodies only
to Env, and six cats produced anti-Gag antibodies at
levels that would not be detectable using a commercial
diagnostic test for FIV. The remaining six cats produced
substantial titers to Gag and/or Env (Table 1). Almost
all Gag and Env specific viral titers in vaginal wash were
less than 1:256 or below the limit of detection for either
IgA or IgG. Thus, using our highly sensitive ELISA, 88%
of the cats seroconverted.
Immune responses associated with control of viremia
Given the trends identified for innate, cell-mediated and
humoral responses, we next determined if any of these
responses correlated with control of viremia. In Figure
7, Spearman correlations are shown for NK cell subsets
(A), draining lymph node and LPL production of IL-2
and IFNg by CD4 and CD8 T cells (B), and serum Gag
and Env titers (C).
Significant inverse correlations to viremia were identi-
fied in both PBMC and Spleen CD56+CD3- NK cells,
w i t hr=- 0 . 5 1a n dr=- 0 . 5 2r e s p e c t i v e l y( F i g u r e7 A ) .
Cell mediated responses in the draining lymph node
suggested a trend associated with anti-Env responses in
CD4 and CD8 T cells producing IL-2, however this was
not significant. Surprisingly, a significant positive corre-
lation with viremia was identified for LPL CD4 T cells
producing IL-2 in response to Gag (r = 0.51). Additional
trends suggested T cell responses to Env in LPL may be
associated with viral control; however, these correlations
were not significant (Figure 7B). Antibody titers signifi-
cantly correlated with the presence and magnitude of
viremia, with anti-Env (r = 0.77) and anti-Gag (r =
0.48). These correlations indicate that higher serum
titers to Env (and Gag to a lesser degree) positively cor-
related with the degree of peak viremia (Figure 7C).
Discussion
Parameters of viral challenge are an important consid-
eration in animal model pathogenesis and vaccine stu-
dies. The majority of human HIV-1 infections occur via
the reproductive mucosa and frequently involve cell-
associated and cell-free forms of virus [41-43]. Further,
leukocyte numbers present in a single human semen
sample can range from 1.0 × 10
4 to 1.0 × 10
8,r e s u l t i n g
in a potentially significant number of HIV-infected leu-
kocytes in seminal fluid [44-46]. The biological rele-
vance of cell-free, high viral dose inocula administered
intravenously or intrarectally is questionable [24]. A goal
Figure 3 Percent CD4+ T cells in peripheral sites eight weeks post-infection. The percent CD4+ T cells is based upon total mononuclear
cells isolated. Mean and standard deviation are shown for control, high, middle and low dose groups at euthanasia. No statistically significant
differences were identified using ANOVA analysis. PBMC, peripheral blood mononuclear cells; PLN, prescapular lymph node; RLN, retropharyngeal
lymph node; ILN, medial iliac lymph node; MLN, mesenteric lymph node; and SPLN, spleen.
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sity found during natural HIV infection and to adminis-
ter the inoculum via the reproductive mucosa. Results
showed that a relatively low dose of cell-free and cell-
associated virus administered vaginally caused infection
in all, yet viremia in only half of the cats. Moreover,
viral dose was unrelated to the development of viremia.
Importantly, regardless of the presence of viremia, all
infected cats had significant changes in mucosal T cell
populations, suggesting that a low dose challenge may
be sufficient to test vaccine efficacy if mucosal pathology
is used as a primary correlate of protection.
For obvious reasons there is great interest in indivi-
duals with transient or controlled HIV-1 infection (thor-
oughly reviewed by Shacklett)[47]. Some studies have
suggested that seronegative persons with high risk of
exposure to HIV-1 may avoid infection as a result of
low viral dose exposure [30,31]. In the present study,
peak viremia was of similar magnitude regardless of
dose, and there were cats in each dose group that did
not become viremic. Thus, while virus dose undoubtedly
plays a role in the likelihood of infection and viremia,
the relationship is not linear and individual immune
responses may be critical.
Of course, determination of virologic status depends
on the sensitivity of methods used and tissue compart-
ments that are evaluated. Clinically measurable serocon-
version was only evident in 1/8 non-viremic cats,
suggesting that these cats have occult infection. In this
study, we used whole bone marrow, which has been
shown to be a site of latency in FIV and other retroviral
infections [48-51], to isolate virus. This method has
been shown to be more sensitive in detecting low levels
of retrovirus than standard real-time PCR techniques
used to identify proviral integration in PBMC [52]. If
standard clinical techniques had been used to determine
the presence of infection, 6/17 cats would have been
categorized as exposed and seronegative. As postulated
by several authors and supported by our results, occult
or latent infection, controlled by innate and cell-
mediated immunity may occur more frequently in
highly-exposed individuals than is currently recognized
[30,31,53-56].
This study also comprehensively evaluated innate, cell-
mediated and humoral immunity. NK cells are an
important innate immune defense, particularly against
intracellular pathogens [57], as they recognize virus
infected cells without requiring costimulatory signals
from other immune system cells, such as dendritic cells.
Given their importance in clearing viral infection, we
assessed the prevalence of total NK, classic (CD56
+CD3-) and NKT cells in PBMC, lymph node and tis-
sues. Decreased NK cell percentages, in general, and
NKT cells, specifically, were associated with FIV infec-
tion while classic NK cells were preserved in non-vire-
mic cats. A significant negative correlation was
identified for CD56+CD3- NK cells and viremia that
suggests innate immunity may play a greater role in
control of acute retroviral infection than previously
believed. Our results are consistent with prior observa-
tions of peripheral CD56+ NK cell loss in HIV-infected
patients [58]. These results are supported by a study
that showed increased NK cell function in highly-
exposed seronegative injecting Vietnamese drug users as
Figure 4 Alterations in mucosal lymphocyte populations eight
weeks post-infection. Box and whisker plots show the median
with upper and lower quartile represented by the boxes, and
minimum and maximum values shown by the whiskers. Percent of
CD4+ T cells in LPL (A), CD8a+ T cells in IEL (B), and CD8b+ T cells
in IEL (C) are shown for control, high, middle and low dose groups
at euthanasia. Statistical significance was calculated using ANOVA,
with p-value shown for FIV-infected groups compared to controls.
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[59]. However, a recent study that examined in vitro NK
cell function of elite controllers suggested a more lim-
ited role for NK cells in control of viral replication [60].
A limitation of the present study is that the effector
function of NK and CD8+ T cells was not evaluated
using an in vitro killing assay. It is also important to
note that increased presence of a specific population, e.
g. NK cells, does not necessarily correlate with their
ability to kill virally infected cells. Therefore, additional
evaluation of NK cell frequency and function in HEPS,
EC and LTNP is needed to better understand their role
and the mechanisms used to control viral replication.
As numerous studies have shown an important role
for cell-mediated immunity in HIV-1 control, we antici-
pated T cell function would be correlated with reduced
viremia. However, correlation of IFN-g and IL-2 produc-
tion by CD4+ and CD8+ T cells yielded surprising
results. A positive correlation to viremia was found for
LPL CD4+ T cell production of IL-2 in response to Gag
stimulation, with a similar trend observed for CD8+
LPL producing IL-2. In addition, while trends for
inverse correlation with viremia were present for drain-
ing lymph node and LPL responses to Env stimulation,
none were significant. This is in spite of significant dif-
ferences in cytokine production when comparing vire-
mic and non-viremic cats. Further, tissue specific
cytokine responses in LPL were evident. Viremic cats
were more likely to produce IFNg and IL-2 against Gag
peptides, whereas non-viremic cats produced IFNg and
IL-2 against Env peptides. However, these responses
were insufficient to prevent the loss of CD4+ LPL and
CD8+ IEL in non-viremic cats. However, we cannot dis-
miss the possibility that these cytokine responses may
have helped reduce mucosal viral reservoirs, preventing
widespread viral dissemination and viremia. As has been
Figure 5 NK cell subsets eight weeks post-infection. Percent NK cells (CD56+) in PBMC, Spleen and IEL for all dose groups of FIV-infected
cats versus control cats (A). Percent of NKT cells (B) and classic NK cells (C) are shown based presence or absence of viremia versus control cats.
Box and whisker plots show the median with upper and lower quartile represented by the boxes, and minimum and maximum values shown
by the whiskers. Statistics were calculated using an unpaired t-test in (A), and based on ANOVA in (B) and (C), with significance shown using p-
values where differences were identified.
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points are typically associated with the production of
IFNg and IL-2 within the same cell, or are typically asso-
ciated with the continued ability to produce IL-2 upon
stimulation [7,61,62]. Our results, similar to Pahar et al.
[63] suggest that control of viremia cannot be directly
correlated with cell-mediated immunity. Further, Barry
et al. [64] showed that depletion of CD8+ T cells in
non-pathogenic infection of sooty mangabey monkeys
did not play a role in control of viral replication. In
addition, others have shown in HIV+ patients that cell-
mediated immunity did not correctly predict the
outcome of infection and AIDS-free survival time
[65,66]. Collectively, these results suggest that robust
cell-mediated immune responses may not be an accurate
correlate of protection.
Another surprising result was the strong positive cor-
relation between anti-Env antibody production and the
level of viremia. Studies of HIV-1 infected patients and
SIV-infected non-human primates have divergent results
with respect to anti-Env antibody responses and their
role in altering progression of disease course. Some have
shown that individuals with profound antibody
responses progressed rapidly to AIDS [67-69]. However,
Figure 6 Intracellular cytokine expression of IFNg and IL-2 by CD4+ and CD8+ T cells eight weeks post-infection. Expression of IFNg is
shown in the top panels, IL-2 in the middle panels and dual expressing (IFNg+IL-2+) in the bottom panels for CD4+ T cells (A) and CD8+ T cells
(B). Individual data points are shown with mean expression indicated by a line for each data set. Significant differences in cytokine expression
are indicated by a line over the applicable data sets and p-value indicated. Calculations were made using an unpaired t-test.
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tion of anti-Env antibodies with HIV-1 disease progres-
sion or no discernable pattern at all [70-74]. Our results
showed that anti-Env and to a lesser degree anti-Gag
antibody responses were associated with measurable
infection, rather than occult infection. One possible
explanation for this result is that significant levels of
antibody were produced as a result of poor control by
innate and cell-mediated immunity. Another possibility
is that although antibodies were produced at high titers,
they may not have been capable of virus neutralization.
Several studies of mucosal pathogenesis in HIV-1
infected humans and SIV infected macaques have
focused on depletion of CD4+ LPL, as they are a pri-
mary target of infection [75-78]. However, it has been
suggested that mucosal immune dysfunction may not be
due solely to CD4+ LPL depletion. It has been shown
that microbial translocation is a source of chronic anti-
genic stimulation in HIV infection [79], and that epithe-
lial barrier dysfunction is evident in cellular and
molecular processes prior to seroconversion [80]. Given
the paucity of studies evaluating the important effector
T cell population present in the epithelium, IEL were
evaluated in conjunction with LPL in this study. Our
results demonstrated that losses of IEL were as signifi-
cant as the loss of CD4+ LPL. We have previously
shown that CD8+ IEL are significantly depleted as early
as one day following FIV infection [81]. The results of
the present study suggest these early losses are not tran-
sient and occur specifically in the CD8ab+ IEL. The
combination of their loss with the loss of CD4+ LPL
suggests that multiple immunologic factors may be
involved in AIDS-associated enteropathy.
A key observation in this study was that all cats,
regardless of initial viral dose, experienced profound
acute losses in mucosal lymphocyte populations. In a
previous study we demonstrated that protected vacci-
nated cats had mucosal immune populations similar to
control cats one year after FIV infection, while unvacci-
nated cats that were non-viremic had disruptions in
their mucosal lymphoid compartment [52]. In addition,
non-pathogenic SIV infection of non-human primates
has also shown that an initial loss of mucosal lympho-
cytes occurs, but when examined at later time points,
these populations have been restored [82]. Collectively,
these findings suggest that mucosal lymphocytes are the
most sensitive indicator of infection as they are dis-
rupted regardless of initial viral dose and seroconversion
status, indicating that vaccine studies could indeed use
preservation of IEL and LPL populations as a correlate
of protection.
Conclusions
In summary, this study provides valuable insight into
the immune responses associated with early viral control
in FIV infection. We found that NK cells may play a
greater role in acute viral control than previously
believed; however, other immune responses were asso-
ciated with the ability of some of these cats to control
viremia, and prevent seroconversion. We also show that
more attention must be directed to dissecting immune
responses not previously addressed in acute pathogen-
esis, with particular attention to innate immunity.
Further, we identified the intestinal mucosa as a very
sensitive indicator of retroviral infection that is indepen-
dent of viral dose and seroconversion. Collectively, our
data suggest that low dose challenge may be sufficient
to test vaccine efficacy when considering mucosal
immune integrity as a primary correlate of protection.
Methods
Animals and challenge inoculums
Twenty-three specific pathogen free (SPF) cats were
obtained from Liberty Labs (Liberty, NY), group housed
and cared for in accordance with AAALAC standards
and IACUC guidelines. FIV-infected female cats
included high dose (n = 6), middle dose (n = 6) and low
dose (n = 5); control cats (n = 6) included 4 female and
2 neutered males. Age was six to eighteen months at
euthanasia.Cats were infected with cell-associated and
cell-free NCSU1, a FIV pathogenic sub-group A virus
Table 1 Anti-p24 and anti-Env IgA and IgG antibody
responses
Vaginal IgA Vaginal
IgG
Serum IgG
Group Cat Gag
1 Env Gag Env Gag Env
High Dose IQW3 128 128 0 32 1,048,576 262,144
IQX7 128 0 0 0 4,096 512
IRB5 0 0 64 0 0 512
IRE5 0 0 0 256 262,144 2,097,152
IRI4 64 64 64 0 4,096 0
IRK4 64 32 32 0 2,048 128
Middle Dose IQT2 0 0 0 0 0 0
IQW5 0 0 64 64 131,072 524,288
IQX6 0 0 256 0 1,024 0
IRB4 0 32 0 0 1,024 512
IRE3 0 0 0 0 0 512
IRK5 1,024 32 256 0 131,072 64
Low Dose IQT3 32 0 0 0 0 0
IQW4 4,096 128 256 128 262,144 2,097,152
IRB3 32 32 0 0 0 1,024
IRK3 0 0 0 0 65,536 0
IRK6 128 64 256 0 4,096 512
1 Endpoint titer.
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viremia to determine if specific immune responses could be responsible for control of viremia. Shown are innate immune responses by CD56
+CD3- and CD56+CD3+ NK cells in PBMC and spleen (A), cell-mediated responses by CD4+ and CD8+ T cells in draining lymph node and LPL
(B), and humoral response using endpoint Env and Gag titers (C). Spearman correlations are shown, with p-values indicated.
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nously inoculating a SPF cat with FIV-positive cells and
harvesting all lymph nodes, spleen, and thymus after six
weeks. Lymphocytes obtained were cultured for 7 days
to increase the proportion of FIV-positive cells, and
then cryopreserved. Supernatants from cultured cells
were used to purify cell-free stocks. Cats were intravag-
inally inoculated with 3.75 × 10
5 FIV positive cells and
9.75 × 10
4 TCID50 cell-free FIV (high dose), 1.88 × 10
5,
FIV positive cells and 4.87 × 10
4 TCID50 cell-free FIV
(middle dose) or 9.3 × 10
4 FIV positive cells and 2.43 ×
10
4 TCID50 cell-free inoculum in RPMI, or were unex-
posed controls. Briefly, cats were sedated and placed in
sternal recumbency with a small rolled towel placed
under their caudal abdomen to elevate the reproductive
tract. Cell-associated and cell-free viral inoculums were
combined immediately prior to administration in a ster-
ile microcentrifuge tube. The inoculum was atraumati-
cally deposited on the mucosal surface of the vaginal
vault using using a pipettor with a blunt polypropylene
pipette tip and was completely absorbed in approxi-
mately five minutes.
Inoculum dose was determined based upon the
results of several mucosal inoculation studies. We have
previously used a combined dose of 7.5 × 10
4 FIV
positive cells and 7.5 × 10
4 TCID50 cell-free and
infected 6/10 control cats [74]. Other studies using the
NCSU1 showed that all cats vaginally inoculated with
10
4 -1 0
6 FIV-positive cells became FIV-positive,
whereas those infected with 10
3 -1 0
2 FIV-positive
cells were either negative or latently positive [56].
Another study employing mucosal infection using a
clade B virus strain, found that cats inoculated with
2.0 × 10
5 but not 2.0 × 10
3 FIV-positive cells were
infected three weeks post-inoculation [43]. Given the
results of these studies, and a prior pilot study (data
not shown), inoculum doses were chosen for this
study, with approximately one log difference in dose
from the high to low dose inoculums.
Sample collection and processing
Plasma, serum and vaginal wash fluids were collected
a tw e e k s0 ,2 ,4 ,6 ,a n d8p o s t - i n f e c t i o na n dp r o c e s s e d
[83]. Peripheral blood mononuclear cells (PBMC),
prescapular lymph node (PLN), mesenteric lymph
node (MLN), medial iliac lymph node (ILN), spleen,
bone marrow and distal jejunum were harvested at
necropsy. Blood for PBMC isolation was collected at
w e e k s0 ,2 ,4 ,6 ,a n d8i nA C Dt u b e s ,a n di s o l a t e d
using Histopaque (Sigma, St Louis, MO) density cen-
trifugation [52]. Lymph nodes, thymus [84] and
spleens [85] were processed as previously described.
Bone marrow collected from the femur was disso-
ciated using mesh screens. After washing, pellets were
lysed with ammonium chloride lysis buffer, washed
twice and counted. Intraepithelial lymphocytes (IEL)
and lamina propria lymphocytes (LPL) were isolated
from distal jejunum following excision of Peyer’s
patches and lymphoid follicles, as previously
described [84].
Real-time FIV RNA PCR
Real-time PCR to detect viral RNA in plasma was per-
formed as previously described [86], with minor modifi-
cations. Real-time PCR was run on a Biorad MyIQ
using continuous RT-PCR at 48°C for 30 minutes, 95°C
for 10 minutes, followed by 45 cycles of 95°C for 10 sec-
onds and 57.5°C for 1 minute. The limit of detection for
this assay is ≤ 10 copies per 45 μl of plasma.
Real-time FIV DNA PCR
Real time PCR was performed to quantify FIV provirus
[87] using previously described primers and probe [86].
DNA was extracted using the DNeasy Tissue Kit (Qia-
gen, Valencia, CA). Real-time PCR reaction contained
300 nM forward primer, 400 nM reverse primer, and 80
nM probe, ABI Universal Mastermix (Applied Biosys-
tems, Foster City, CA), water and DNA sample. The
feline genome contains one copy of the CCR5 sequence
and was used to normalize FIV copy number. The
CCR5 primers (forward 5’-ACGTCTACCTGCT-
CAACCTGG-3’,r e v e r s e5 ’-ACCGTCTTACACATCC-
CATCCC-3’)a n dp r o b e( F A M - 5 ’-TCCGACCTGCT-
CTTCCTCTTCACCCTCC-3’) were designed using
Beacon Designer. PCR reactions for CCR5 were run on
a separate plate using 200 nM forward primer, 500 nM
reverse primer, and 200 nM probe, ABI Universal Mas-
ter mix, water and DNA sample. FIV and CCR5 plates
were run sequentially on the same instrument. All stan-
dard dilutions, controls and samples were run in dupli-
cate. The limit of detection was ≤10 copies of FIV per 1
μg DNA.
Virus isolation
Cryopreserved bone marrow samples were thawed,
washed, counted and 1.5 × 10
5 co-cultured with 3.0
×1 0
5 FCD4-Ecells or Mya-1 cells, both of which are
FIV susceptible cell lines, in triplicate in LBT med-
ium supplemented with 100U/ml recombinant
human IL-2 (AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH: contributed
by Hoffman-La Roche Inc.). Supernatants were ana-
lyzed for FIV p24 by antigen capture ELISA at 16
and 20 days of culture [52]. In addition, cells were
analyzed for intracellular viral antigen by FACS at 20
days of culture using the BD Cytofix/Cytoperm kit
and FITC conjugated anti-FIV monoclonal antibody
43-1B9.
Howard et al. Retrovirology 2010, 7:2
http://www.retrovirology.com/content/7/1/2
Page 10 of 14Monoclonal antibodies
Monoclonal antibodies (mAb) used for cell surface
staining were directly conjugated to FITC, PE, biotin,
PerCP, APC, PECy7, or Alexa 700. Previously
described antibodies included anti-CD4 (3-4F4), anti-
CD8a (3.357), Streptavidin-PerCP, and Streptavidin-
APC [84]. Other antibodies included anti-feline CD8b
and Streptavidin-Pe-Cy7 (Southern Biotechnology, Bir-
mingham, AL); anti-CD56 (clone C5.9, Dako, Carpin-
teria, CA); anti-tumor necrosis factor alpha (TNFa,
c l o n e6 4 0 1 . 1 1 1 1 ,B DB i o s c i e n c e s ,S a nJ o s e ,C A ) ;a n t i -
interleukin-2 (IL2, clone MQ1-17H12, Biolegend, San
Diego, CA), and anti-interferon gamma (IFNg,c l o n e
E4A3B9) made in our laboratory. Anti-feline CD3
(clone NZM1), a generous gift from T. Miyazawa
(Univ. of Tokyo, Japan) detected with anti-mouse IgG3
APC (#115-135-209, Jackson Immunoresearch, West
Grove, PA). Staining and flow cytometric analysis were
performed as previously described [84]. Samples were
fixed with 4% paraformaldehyde, collected on a BD
LSRII (BD Immunocytometry Systems, San Jose, CA)
flow cytometer, and analyzed with BD FACS Diva
software.
Intracellular cytokine production
PBMC, spleen, PLN, ILN, IEL and LPL were cultured
overnight in LBT medium without stimulation. Cells
were then stimulated with either Gag or Env peptide
pools, Con A, or media alone for six hours, with 1.5 μl/
ml of 1x Monensin (Biolegend, San Diego, CA) present
for the final five hours. Following culture, cells were
washed with PBS and stained with antibodies to CD4
and CD8, washed, and fixed with 4% paraformaldehyde
(PFA) for ten minutes, then washed and resuspended in
PBS/2%FBS, covered and stored at -4°C. Within 24-48
hours of PFA fixation, cells were washed with Perm/
Wash Buffer (BD Cytofix/Cytoperm), stained with anti-
bodies to IFNg,I L - 2 ,a n dT N F a for 30 minutes, washed
and analyzed immediately, collecting 100,000 gated
events whenever possible. For analysis, cell populations
were initially gated to identify the viable leukocyte popu-
lation on FSC and SSC. Using this gate, CD4+ and CD8
+ T cells were individually gated and CD4+ and CD8+
T cells producing IL-2, IFNg and TNFa in response to
Gag or Env peptide stimulation identified (Additional
file 1). The percentage of T cells responding to stimula-
tion was calculated by subtracting the cytokine response
detected in cells from the same sample stimulated with
media alone.
FIV p24 antibody chemiluminescent ELISA
Chromalux™ HB Luminescent Assay microplates
(Dynex Technologies Inc., Chantilly, VA) were coated
with 1.0 μg/ml p24-GST fusion protein [88] and
ELISA completed as previously described [89] with
minor modifications. Blocking buffer contained CBC
buffer with 5% nonfat dry milk and 0.1% Kathon.
ELISA wash buffer (EWB) contained PBS, 0.05%
Tween-20, and 0.1% Kathon. Samples were serially
diluted in sample diluent (PBS, 5% non-fat dry milk,
5% goat serum, 0.05% Tween-20 and 0.1% Kathon),
added to ELISA plates at 100 μl/well, covered and
incubated for three hours at 37°C, then washed six
times with EWB. Antibody was detected with goat
anti-cat IgG (Bethyl Labs, Montgomery, TX) or goat
anti-IgA (Serotec, Raleigh, NC) diluted 1:80,000 and
1:3,000 respectively in sample diluent, covered, incu-
bated one hour at 25°C, then washed six times with
EWB. Plates were developed with 100 μl/well Pierce
SuperSignal ELISA Femto Chemiluminescent substrate
#37074 and read five minutes after addition of sub-
strate (Perkin-Elmer Victor 3 1420 Multilabel Coun-
ter). Antibody titers were considered positive if they
were two-fold greater than the naïve serum/vaginal
w a s hs a m p l ef o rt h es a m ei n d i v i d u a l .
FIV Env antibody chemiluminescent ELISA
Anti-envelope responses were measured using a pre-
viously described envelope fusion protein (gp95-FC)
[90]. Anti-Env ELISA was completed as described for
anti-p24 antibody ELISA with minor modifications.
Blocking buffer contained CBC buffer with 3% non-fat
dry milk, 5% goat serum, and 0.1% Kathon. Sample dilu-
ent contained PBS, 1% BSA, 1% non-fat dry milk, 2.5%
human serum, 0.05% Tween-20 and 0.1% Kathon. Plates
were coated with 100 μl/well of gp95-FC at 2.5 μg/ml in
sample diluent. Sample dilutions were incubated for 30
minutes at 25°C prior to loading 100 μl/well to ELISA
plates. Secondary antibodies for anti-IgG and anti-IgA
detection were diluted to 1:60,000 and 1:3,000
respectively.
Statistical analysis
Comparison of viremic versus non-viremic FIV inocu-
lated cats was completed using an unpaired t-test. Sta-
tistical analysis of differentially FIV-inoculated groups
and control cats utilized a one-way analysis of variance
(ANOVA) with a Tukey-Kramer multiple comparison
post-test or nonparametric ANOVA (Kruskal-Wallis
test) with Dunn’s multiple comparison post-test. The
choice of test was dictated by testing the assumptions
necessary for parametric methods, such that if a para-
metric method was not appropriate, non-parametric
testing was used. Significance was defined as p ≤ 0.05.
Analyses were completed using GraphPad InStat version
3.05 (GraphPad Software, San Diego, CA).
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Page 11 of 14Additional File 1: Supplemental Figure 1. Gating strategy for
intracellular cytokine assessment. Samples stained for surface and
intracellular antigens were gated based on forward and side scatter (A).
The gated population was used to identify CD4+ and CD8+ T cells (B).
Using either CD4+ or CD8+ T cells as the parent gate, specific staining
for IFNg (y-axis) and IL-2 (x-axis) are shown for unstimulated (C) and
stimulated samples (D) from the same medial iliac lymph node. For
analysis, the percent of cells staining positively in unstimulated samples
was subtracted from stimulated samples to determine net cytokine
production reported in Figure 6.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-4690-7-2-
S1.BMP]
Acknowledgements
We thank Dr. Shila Nordone for her assistance in developing the
chemiluminescent ELISA assays and Dr. Susan Lankford for her assistance
with real-time FIV DNA PCR. We also thank Chasity Jones and Emily Smith
for their technical assistance. This study was funded by NIH/NIAID
R21AI065223 (GD) and NIH/NIAID K08 AI056984 (KH).
Author details
1Center for Comparative Medicine and Translational Research, Department of
Molecular Biomedical Sciences, College of Veterinary Medicine, North
Carolina State University, Raleigh, NC, 27606, USA.
2Current address:
Immunobio, 920 Main Campus Drive, Suite 405, Raleigh, NC, 27606, USA.
Authors’ contributions
KH designed and coordinated the study, collected and processed biological
samples, performed FACS assays and virus isolation, analyzed data,
performed statistical analysis and drafted the manuscript. SR helped design
the study, collected and processed biological samples, performed FACS
assays and assisted in data analysis. EE collected and processed biological
samples, performed PCR and ELISA assays and assisted in data analysis. GD
helped design the study, critically reviewed the results and helped to draft
the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 4 August 2009
Accepted: 19 January 2010 Published: 19 January 2010
References
1. HIV vaccine failure prompts Merck to halt trial. Nature 2007, 449:390.
2. Vaccine trial discontinued. AIDS Patient Care STDS 2007, 21:778-779.
3. Cohen J: AIDS research. Promising AIDS vaccine’s failure leaves field
reeling. Science 2007, 318:28-29.
4. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S,
Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS,
Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN,
Mehrotra DV, Quirk E, Merck V520-016 Study Group: Safety and
immunogenicity of a replication-incompetent adenovirus type 5 HIV-1
clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008,
46:1769-1781.
5. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D,
Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR,
Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN, Step Study
Protocol Team: Efficacy assessment of a cell-mediated immunity HIV-1
vaccine (the Step Study): a double-blind, randomised, placebo-
controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
6. Heeney JL, Plotkin SA: Immunological correlates of protection from HIV
infection and disease. Nat Immunol 2006, 7:1281-1284.
7. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J,
Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA:
HIV nonprogressors preferentially maintain highly functional HIV-specific
CD8+ T cells. Blood 2006, 107:4781-4789.
8. Kaul R, Rowland-Jones SL, Kimani J, Fowke K, Dong T, Kiama P, Rutherford J,
Njagi E, Mwangi F, Rostron T, Onyango J, Oyugi J, MacDonald KS, Bwayo JJ,
Plummer FA: New insights into HIV-1 specific cytotoxic T-lymphocyte
responses in exposed, persistently seronegative Kenyan sex workers.
Immunol Lett 2001, 79:3-13.
9. Addo MM, Draenert R, Rathod A, Verrill CL, Davis BT, Gandhi RT,
Robbins GK, Basgoz NO, Stone DR, Cohen DE, Johnston MN, Flynn T,
Wurcel AG, Rosenberg ES, Altfeld M, Walker BD: Fully differentiated HIV-1
specific CD8+ T effector cells are more frequently detectable in
controlled than in progressive HIV-1 infection. PLoS ONE 2007, 2:e321.
10. Gea-Banacloche JC, Migueles SA, Martino L, Shupert WL, McNeil AC,
Sabbaghian MS, Ehler L, Prussin C, Stevens R, Lambert L, Altman J,
Hallahan CW, de Quiros JC, Connors M: Maintenance of large numbers of
virus-specific CD8+ T cells in HIV-infected progressors and long-term
nonprogressors. J Immunol 2000, 165:1082-1092.
11. Lamine A, Caumont-Sarcos A, Chaix ML, Saez-Cirion A, Rouzioux C,
Delfraissy JF, Pancino G, Lambotte O: Replication-competent HIV strains
infect HIV controllers despite undetectable viremia (ANRS EP36 study).
Aids 2007, 21:1043-1045.
12. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F,
Barre-Sinoussi F, Delfraissy JF, Sinet M, Pancino G, Venet A: HIV controllers
exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and
peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci
USA 2007, 104:6776-6781.
13. Hladik F, Desbien A, Lang J, Wang L, Ding Y, Holte S, Wilson A, Xu Y,
Moerbe M, Schmechel S, McElrath MJ: Most highly exposed seronegative
men lack HIV-1-specific, IFN-gamma-secreting T cells. J Immunol 2003,
171:2671-2683.
14. Mansfield K, Lang SM, Gauduin MC, Sanford HB, Lifson JD, Johnson RP,
Desrosiers RC: Vaccine protection by live, attenuated simian
immunodeficiency virus in the absence of high-titer antibody responses
and high-frequency cellular immune responses measurable in the
periphery. J Virol 2008, 82:4135-4148.
15. Nguyen M, Pean P, Lopalco L, Nouhin J, Phoung V, Ly N, Vermisse P,
Henin Y, Barre-Sinoussi F, Burastero SE, Reynes JM, Carcelain G, Pancino G:
HIV-specific antibodies but not t-cell responses are associated with
protection in seronegative partners of HIV-1-infected individuals in
Cambodia. J Acquir Immune Defic Syndr 2006, 42:412-419.
16. Schmechel SC, Russell N, Hladik F, Lang J, Wilson A, Ha R, Desbien A,
McElrath MJ: Immune defence against HIV-1 infection in HIV-1-exposed
seronegative persons. Immunol Lett 2001, 79:21-27.
17. Sadoff JC, Wittes J: Correlates, surrogates, and vaccines. J Infect Dis 2007,
196:1279-1281.
18. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG: A framework for assessing
immunological correlates of protection in vaccine trials. J Infect Dis 2007,
196:1304-1312.
19. Casimiro DR, Wang F, Schleif WA, Liang X, Zhang ZQ, Tobery TW,
Davies ME, McDermott AB, O’Connor DH, Fridman A, Bagchi A, Tussey LG,
Bett AJ, Finnefrock AC, Fu TM, Tang A, Wilson KA, Chen M, Perry HC,
Heidecker GJ, Freed DC, Carella A, Punt KS, Sykes KJ, Huang L, Ausensi VI,
Bachinsky M, Sadasivan-Nair U, Watkins DI, Emini EA, Shiver JW: Attenuation
of simian immunodeficiency virus SIVmac239 infection by prophylactic
immunization with dna and recombinant adenoviral vaccine vectors
expressing Gag. J Virol 2005, 79:15547-15555.
20. Wilson NA, Reed J, Napoe GS, Piaskowski S, Szymanski A, Furlott J,
Gonzalez EJ, Yant LJ, Maness NJ, May GE, Soma T, Reynolds MR, Rakasz E,
Rudersdorf R, McDermott AB, O’Connor DH, Friedrich TC, Allison DB, Patki A,
Picker LJ, Burton DR, Lin J, Huang L, Patel D, Heindecker G, Fan J, Citron M,
Horton M, Wang F, Liang X, Shiver JW, Casimiro DR, Watkins DI: Vaccine-
induced cellular immune responses reduce plasma viral concentrations
after repeated low-dose challenge with pathogenic simian
immunodeficiency virus SIVmac239. J Virol 2006, 80:5875-5885.
21. Mattapallil JJ, Douek DC, Buckler-White A, Montefiori D, Letvin NL, Nabel GJ,
Roederer M: Vaccination preserves CD4 memory T cells during acute
simian immunodeficiency virus challenge. J Exp Med 2006, 203:1533-1541.
22. Buge SL, Murty L, Arora K, Kalyanaraman VS, Markham PD, Richardson ES,
Aldrich K, Patterson LJ, Miller CJ, Cheng SM, Robert-Guroff M: Factors
associated with slow disease progression in macaques immunized with
an adenovirus-simian immunodeficiency virus (SIV) envelope priming-
gp120 boosting regimen and challenged vaginally with SIVmac251. J
Virol 1999, 73:7430-7440.
Howard et al. Retrovirology 2010, 7:2
http://www.retrovirology.com/content/7/1/2
Page 12 of 1423. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ,
Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X,
Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A,
Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC,
Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H,
Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB,
Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE,
Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA: Replication-
incompetent adenoviral vaccine vector elicits effective anti-
immunodeficiency-virus immunity. Nature 2002, 415:331-335.
24. Regoes RR, Longini IM, Feinberg MB, Staprans SI: Preclinical assessment of
HIV vaccines and microbicides by repeated low-dose virus challenges.
PLoS Med 2005, 2:e249.
25. AIDS Epidemic Update:December 2008. WHO/UNAIDS Joint United
Nations Programme on HIV/AIDS 2008.
26. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM: Relation between
HIV viral load and infectiousness: a model-based analysis. Lancet 2008,
372:314-320.
27. Kaizu M, Weiler AM, Weisgrau KL, Vielhuber KA, May G, Piaskowski SM,
Furlott J, Maness NJ, Friedrich TC, Loffredo JT, Usborne A, Rakasz EG:
Repeated intravaginal inoculation with cell-associated simian
immunodeficiency virus results in persistent infection of nonhuman
primates. J Infect Dis 2006, 194:912-916.
28. Ma ZM, Abel K, Rourke T, Wang Y, Miller CJ: A period of transient viremia
and occult infection precedes persistent viremia and antiviral immune
responses during multiple low-dose intravaginal simian
immunodeficiency virus inoculations. J Virol 2004, 78:14048-14052.
29. McDermott AB, Mitchen J, Piaskowski S, De Souza I, Yant LJ, Stephany J,
Furlott J, Watkins DI: Repeated low-dose mucosal simian
immunodeficiency virus SIVmac239 challenge results in the same viral
and immunological kinetics as high-dose challenge: a model for the
evaluation of vaccine efficacy in nonhuman primates. J Virol 2004,
78:3140-3144.
30. Assogba BD, Leavell S, Porter K, Burkhard MJ: Mucosal administration of
low-dose cell-associated feline immunodeficiency virus promotes viral
latency. J Infect Dis 2007, 195:1184-1188.
31. McChesney MB, Collins JR, Lu D, Lu X, Torten J, Ashley RL, Cloyd MW,
Miller CJ: Occult systemic infection and persistent simian
immunodeficiency virus (SIV)-specific CD4(+)-T-cell proliferative
responses in rhesus macaques that were transiently viremic after
intravaginal inoculation of SIV. J Virol 1998, 72:10029-10035.
32. Zhu T, Corey L, Hwangbo Y, Lee JM, Learn GH, Mullins JI, McElrath MJ:
Persistence of extraordinarily low levels of genetically homogeneous
human immunodeficiency virus type 1 in exposed seronegative
individuals. J Virol 2003, 77:6108-6116.
33. Nicastri E, Ercoli L, Sarmati L, d’Ettorre G, Iudicone P, Massetti P, Vullo V,
Andreoni M: Human immunodeficiency virus-1 specific and natural
cellular immunity in HIV seronegative subjects with multiple sexual
exposures to virus. J Med Virol 2001, 64:232-237.
34. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B,
Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T,
Petropoulos CJ, Rosenberg ES, Walker BD: Genetic and immunologic
heterogeneity among persons who control HIV infection in the absence
of therapy. J Infect Dis 2008, 197:563-571.
35. Tompkins MB, Nelson PD, English RV, Novotney C: Early events in the
immunopathogenesis of feline retrovirus infections. J Am Vet Med Assoc
1991, 199:1311-1315.
36. English RV, Nelson P, Johnson CM, Nasisse M, Tompkins WA, Tompkins MB:
Development of clinical disease in cats experimentally infected with
feline immunodeficiency virus. J Infect Dis 1994, 170:543-552.
37. Sparkes AH, Hopper CD, Millard WG, Gruffydd-Jones TJ, Harbour DA: Feline
immunodeficiency virus infection. Clinicopathologic findings in 90
naturally occurring cases. J Vet Intern Med 1993, 7:85-90.
38. Obert LA, Hoover EA: Feline immunodeficiency virus clade C mucosal
transmission and disease courses. AIDS Res Hum Retroviruses 2000,
16:677-688.
39. Allison RW, Hoover EA: Covert vertical transmission of feline
immunodeficiency virus. AIDS Res Hum Retroviruses 2003, 19:421-434.
40. Dean GA, LaVoy A, Burkhard MJ: Peptide mapping of feline
immunodeficiency virus by IFN-gamma ELISPOT. Vet Immunol
Immunopathol 2004, 100:49M-59.
41. Krieger JN, Coombs RW, Collier AC, Ross SO, Chaloupka K, Cummings DK,
Murphy VL, Corey L: Recovery of human immunodeficiency virus type 1
from semen: minimal impact of stage of infection and current antiviral
chemotherapy. Infect Dis J 1991, 163:386-388.
42. Plummer FA, Simonsen JN, Cameron DW, Ndinya-Achola JO, Kreiss JK,
Gakinya MN, Waiyaki P, Cheang M, Piot P, Ronald AR, et al: Cofactors in
male-female sexual transmission of human immunodeficiency virus type
1. J Infect Dis 1991, 163:233-239.
43. Spinillo A, Zara F, De Santolo A, Brerra R, Maserati R, Romero E, Filice G:
Quantitative assessment of cell-associated and cell-free virus in
cervicovaginal samples of HIV-1-infected women. Clin Microbiol Infect
1999, 5:605-611.
44. Politch JA, Wolff H, Hill JA, Anderson DJ: Comparison of methods to
enumerate white blood cells in semen. Fertil Steril 1993, 60:372-375.
45. Wolff H, Anderson DJ: Male genital tract inflammation associated with
increased numbers of potential human immunodeficiency virus host
cells in semen. Andrologia 1988, 20:404-410.
46. Wolff H, Anderson DJ: Immunohistologic characterization and
quantitation of leukocyte subpopulations in human semen. Fertil Steril
1988, 49:497-504.
47. Shacklett BL: Understanding the “lucky few": the conundrum of HIV-
exposed, seronegative individuals. Curr HIV/AIDS Rep 2006, 3:26-31.
48. Dandekar S, Beebe AM, Barlough J, Phillips T, Elder J, Torten M, Pedersen N:
Detection of feline immunodeficiency virus (FIV) nucleic acids in FIV-
seronegative cats. J Virol 1992, 66:4040-4049.
49. Sandy JR, Robinson WF, Bredhauer B, Kyaw-Tanner M, Howlett CR:
Productive infection of the bone marrow cells in feline
immunodeficiency virus infected cats. Arch Virol 2002, 147:1053-1059.
50. Rojko JL, Hoover EA, Quackenbush SL, Olsen RG: Reactivation of latent
feline leukaemia virus infection. Nature 1982, 298:385-388.
51. Siebelink KH, Chu IH, Rimmelzwaan GF, Weijer K, Osterhaus AD, Bosch ML:
Isolation and partial characterization of infectious molecular clones of
feline immunodeficiency virus obtained directly from bone marrow DNA
of a naturally infected cat. J Virol 1992, 66:1091-1097.
52. Stevens R, Howard KE, Nordone S, Burkhard M, Dean GA: Oral
immunization with recombinant listeria monocytogenes controls virus
load after vaginal challenge with feline immunodeficiency virus. J Virol
2004, 78:8210-8218.
53. Sahu GK, Chen JJ, Huang JC, Ramsey KM, Cloyd MW: Transient or occult
HIV-1 infection in high-risk adults. Aids 2001, 15:1175-1177.
54. Sahu GK, McNearney T, Evans A, Turner A, Weaver S, Huang JC, Baron S,
Paar D, Cloyd MW: Transient or occult HIV infections may occur more
frequently than progressive infections: changing the paradigm about
HIV persistence. Arch Virol Suppl 2005, 131-145.
55. Tenenbaum SA, Morris CA, Alexander SS, McFerrin HE, Garry RF,
Leissinger CA: Evidence of HIV exposure and transient seroreactivity in
archived HIV-negative severe hemophiliac sera. Virol J 2005, 2:65.
56. Uberla K: HIV vaccine development in the aftermath of the STEP study:
re-focus on occult HIV infection?. PLoS Pathog 2008, 4:e1000114.
57. Fortis C, Poli G: Dendritic cells and natural killer cells in the pathogenesis
of HIV infection. Immunol Res 2005, 33:1-21.
58. Alter G, Altfeld M: NK cells in HIV-1 infection: evidence for their role in
the control of HIV-1 infection. J Intern Med 2009, 265:29-42.
59. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, Nguyen NV,
Theodorou I, Barre-Sinoussi F, Pancino G: Cutting edge: increased NK cell
activity in HIV-1-exposed but uninfected Vietnamese intravascular drug
users. J Immunol 2003, 171:5663-5667.
60. O’Connell KA, Han Y, Williams TM, Siliciano RF, Blankson JN: Role of natural
killer cells in a cohort of elite suppressors: low frequency of the
protective KIR3DS1 allele and limited inhibition of human
immunodeficiency virus type 1 replication in vitro. J Virol 2009,
83:5028-5034.
61. Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, Martin JN, Nixon DF,
McCune JM, Deeks SG: Phenotypic, functional, and kinetic parameters
associated with apparent T-cell control of human immunodeficiency
virus replication in individuals with and without antiretroviral treatment.
J Virol 2005, 79:14169-14178.
62. Daucher M, Price DA, Brenchley JM, Lamoreaux L, Metcalf JA, Rehm C, Nies-
Kraske E, Urban E, Yoder C, Rock D, Gumkowski J, Betts MR, Dybul MR,
Douek DC: Virological Outcome After Structured Interruption of
Antiretroviral Therapy For HIV Infection is Associated with the
Howard et al. Retrovirology 2010, 7:2
http://www.retrovirology.com/content/7/1/2
Page 13 of 14Functional Profile of Virus-Specific CD8+ T-Cells. J Virol 2008,
82:4102-4114.
63. Pahar B, Lackner AA, Piatak M Jr, Lifson JD, Wang X, Das A, Ling B,
Montefiori DC, Veazey RS: Control of viremia and maintenance of
intestinal CD4(+) memory T cells in SHIV(162P3) infected macaques after
pathogenic SIV(MAC251) challenge. Virology 2009, 387:273-284.
64. Barry AP, Silvestri G, Safrit JT, Sumpter B, Kozyr N, McClure HM, Staprans SI,
Feinberg MB: Depletion of CD8+ cells in sooty mangabey monkeys
naturally infected with simian immunodeficiency virus reveals limited
role for immune control of virus replication in a natural host species. J
Immunol 2007, 178:8002-8012.
65. Schellens IM, Borghans JA, Jansen CA, De Cuyper IM, Geskus RB, van
Baarle D, Miedema F: Abundance of early functional HIV-specific CD8+ T
cells does not predict AIDS-free survival time. PLoS One 2008, 3:e2745.
66. Jiao Y, Xie J, Li T, Han Y, Qiu Z, Zuo L, Wang A: Correlation between gag-
specific CD8 T-cell responses, viral load, and CD4 count in HIV-1
infection is dependent on disease status. J Acquir Immune Defic Syndr
2006, 42:263-268.
67. Smith SM, Holland B, Russo C, Dailey PJ, Marx PA, Connor RI: Retrospective
analysis of viral load and SIV antibody responses in rhesus macaques
infected with pathogenic SIV: predictive value for disease progression.
AIDS Res Hum Retroviruses 1999, 15:1691-1701.
68. Beer BE, Brown CR, Whitted S, Goldstein S, Goeken R, Plishka R, Buckler-
White A, Hirsch VM: Immunodeficiency in the absence of high viral load
in pig-tailed macaques infected with Simian immunodeficiency virus
SIVsun or SIVlhoest. J Virol 2005, 79:14044-14056.
69. Staprans SI, Barry AP, Silvestri G, Safrit JT, Kozyr N, Sumpter B, Nguyen H,
McClure H, Montefiori D, Cohen JI, Feinberg MB: Enhanced SIV replication
and accelerated progression to AIDS in macaques primed to mount a
CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci USA
2004, 101:13026-13031.
70. Bruck C, Thiriart C, Fabry L, Francotte M, Pala P, Van Opstal O, Culp J,
Rosenberg M, De Wilde M, Heidt P, Heeney J: HIV-1 envelope-elicited
neutralizing antibody titres correlate with protection and virus load in
chimpanzees. Vaccine 1994, 12:1141-1148.
71. Cao Y, Qin L, Zhang L, Safrit J, Ho DD: Virologic and immunologic
characterization of long-term survivors of human immunodeficiency
virus type 1 infection. N Engl J Med 1995, 332:201-208.
72. Harrer T, Harrer E, Kalams SA, Elbeik T, Staprans SI, Feinberg MB, Cao Y,
Ho DD, Yilma T, Caliendo AM, Johnson RP, Buchbinder SP, Walker BD:
Strong cytotoxic T cell and weak neutralizing antibody responses in a
subset of persons with stable nonprogressing HIV type 1 infection. AIDS
Res Hum Retroviruses 1996, 12:585-592.
73. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, Miralles GD,
Fauci AS: Neutralizing and infection-enhancing antibody responses to
human immunodeficiency virus type 1 in long-term nonprogressors. J
Infect Dis 1996, 173:60-67.
74. Bailey JR, Lassen KG, Yang HC, Quinn TC, Ray SC, Blankson JN, Siliciano RF:
Neutralizing antibodies do not mediate suppression of human
immunodeficiency virus type 1 in elite suppressors or selection of
plasma virus variants in patients on highly active antiretroviral therapy. J
Virol 2006, 80:4758-4770.
75. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ,
Nguyen PL, Khoruts A, Larson M, Haase AT, Douek DC: CD4+ T cell
depletion during all stages of HIV disease occurs predominantly in the
gastrointestinal tract. J Exp Med 2004, 200:749-759.
76. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M: Massive
infection and loss of memory CD4+ T cells in multiple tissues during
acute SIV infection. Nature 2005, 434:1093-1097.
77. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C,
Boden D, Racz P, Markowitz M: Primary HIV-1 infection is associated with
preferential depletion of CD4+ T lymphocytes from effector sites in the
gastrointestinal tract. J Exp Med 2004, 200:761-770.
78. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL,
Rosenzweig M, Johnson RP, Desrosiers RC, Lackner AA: Gastrointestinal
tract as a major site of CD4+ T cell depletion and viral replication in SIV
infection. Science 1998, 280:427-431.
79. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z,
Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-
Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM,
Deeks SG, Douek DC: Microbial translocation is a cause of systemic
immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
80. Sankaran S, George MD, Reay E, Guadalupe M, Flamm J, Prindiville T,
Dandekar S: Rapid onset of intestinal epithelial barrier dysfunction in
primary human immunodeficiency virus infection is driven by an
imbalance between immune response and mucosal repair and
regeneration. J Virol 2008, 82:538-545.
81. Howard KE, Burkhard MJ: Mucosal challenge with cell-associated or cell-
free feline immunodeficiency virus induces rapid and distinctly different
patterns of phenotypic change in the mucosal and systemic immune
systems. Immunology 2007, 122:571-583.
82. Pandrea IV, Gautam R, Ribeiro RM, Brenchley JM, Butler IF, Pattison M,
Rasmussen T, Marx PA, Silvestri G, Lackner AA, Perelson AS, Douek DC,
Veazey RS, Apetrei C: Acute loss of intestinal CD4+ T cells is not
predictive of simian immunodeficiency virus virulence. J Immunol 2007,
179:3035-3046.
83. Burkhard MJ, Mathiason CK, Bowdre T, Hoover EA: Feline
immunodeficiency virus Gag- and Env-specific immune responses after
vaginal versus intravenous infection. AIDS Res Hum Retroviruses 2001,
17:1767-1778.
84. Howard KE, Fisher IL, Dean GA, Burkhard MJ: Methodology for isolation
and phenotypic characterization of feline small intestinal leukocytes. J
Immunol Methods 2005, 302:36-53.
85. Ignacio G, Nordone S, Howard KE, Dean GA: Toll-like receptor expression
in feline lymphoid tissues. Vet Immunol Immunopathol 2005, 106:229-237.
86. Burkhard MJ, Valenski L, Leavell S, Dean GA, Tompkins WA: Evaluation of
FIV protein-expressing VEE-replicon vaccine vectors in cats. Vaccine 2002,
21:258-268.
87. Pedersen NC, Leutenegger CM, Woo J, Higgins J: Virulence differences
between two field isolates of feline immunodeficiency virus (FIV-
APetaluma and FIV-CPGammar) in young adult specific pathogen free
cats. Vet Immunol Immunopathol 2001, 79:53-67.
88. Reid G, Rigby MA, McDonald M, Hosie MJ, Neil JC, Jarrett O:
Immunodiagnosis of feline immunodeficiency virus infection using
recombinant viral p17 and p24. Aids 1991, 5:1477-1483.
89. Staats HF, Nichols WG, Palker TJ: Mucosal immunity to HIV-1: systemic
and vaginal antibody responses after intranasal immunization with the
HIV-1 C4/V3 peptide T1SP10 MN(A). J Immunol 1996, 157:462-472.
90. de Parseval A, Elder JH: Binding of recombinant feline immunodeficiency
virus surface glycoprotein to feline cells: role of CXCR4, cell-surface
heparans, and an unidentified non-CXCR4 receptor. J Virol 2001,
75:4528-4539.
doi:10.1186/1742-4690-7-2
Cite this article as: Howard et al.: Acute mucosal pathogenesis of feline
immunodeficiency virus is independent of viral dose in vaginally
infected cats. Retrovirology 2010 7:2.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Howard et al. Retrovirology 2010, 7:2
http://www.retrovirology.com/content/7/1/2
Page 14 of 14